Icosavax shares are trading higher after the company announced topline interim Phase 1 results for its bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults.
Portfolio Pulse from Benzinga Newsdesk
Icosavax announced positive interim Phase 1 results for its bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults, leading to a rise in its share price.
May 23, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Icosavax shares are trading higher after announcing positive interim Phase 1 results for its IVX-A12 vaccine candidate against RSV and hMPV in older adults.
The positive interim Phase 1 results for Icosavax's IVX-A12 vaccine candidate indicate progress in the development of the vaccine, which could potentially lead to increased demand and revenue for the company. This news is directly related to the company's core business and is likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100